drome type I is not considered a cause, because there is no definable nerve lesion. The epidemiology of neuropathic pain has not been adequately studied, partly because of the diversity of the associated conditions. Current pooled estimates suggest that neuropathic pain may affect as much as 3% of the population.
7-13
The personal impact of neuropathic pain is most vividly appreciated by people who experience this devastating condition. Those affected have described their pain using the McGill Pain Questionnaire 14 with descriptors such as "punishing-cruel" and "tiring-exhausting." 15, 16 Ample evidence indicates that neuropathic pain impairs patients' mood, quality of life, activities of daily living and performance at work. 9, 17, 18 People with the condition have been found to generate 3-fold higher health care costs compared with matched controls. 19 In the United States, health care, disability and related costs associated with chronic pain have been estimated at $150 billion annually, 20 of which almost $40 billion is attributable to neuropathic pain.
Clinical presentation and patient evaluation
The blockade of nerve conduction in neuropathic conditions causes nerve dysfunction, which can result in numbness, weakness and loss of deep tendon reflexes in the affected nerve area. Neuropathic conditions also cause aberrant symptoms of spontaneous and stimulus-evoked pain. Spontaneous pain (continuous or intermittent) is commonly described as burning, shooting or shock-like. 15, [21] [22] [23] [24] [25] [26] Stimulusevoked pain includes allodynia (pain evoked by a nonpainful touch) and hyperalgesia (increased pain evoked by a painful stimulus). Allodynia can be caused by the lightest stimulation, such as skin contact with clothing or a light breeze. These sensory abnormalities may extend beyond nerve distributions ( Fig. 1) , which may lead to the inappropriate diagnosis of a functional or psychosomatic disorder. The diagnosis of neuropathic pain is based primarily on history and findings on physical examination.
Neuropathic pain, caused by various central and peripheral nerve disorders, is especially problematic because of its severity, chronicity and resistance to simple analgesics. The condition affects 2%-3% of the population, is costly to the health care system and is personally devastating to the people who experience it. The diagnosis of neuropathic pain is based primarily on history (e.g., underlying disorder and distinct pain qualities) and the findings on physical examination (e.g., pattern of sensory disturbance); however, several tests may sometimes be helpful. Important pathophysiologic mechanisms include sodium-and calcium-channel upregulation, spinal hyperexcitability, descending facilitation and aberrant sympathetic-somatic nervous system interactions. Treatments are generally palliative and include conservative nonpharmacologic therapies, drugs and more invasive interventions (e.g., spinal cord stimulation). Individualizing treatment requires consideration of the functional impact of the neuropathic pain (e.g., depression, disability) as well as ongoing evaluation, patient education, reassurance and specialty referral. We propose a primary care algorithm for treatments with the most favourable risk-benefit profile, including topical lidocaine, gabapentin, pregabalin, tricyclic antidepressants, mixed serotonin-norepinephrine reuptake inhibitors, tramadol and opioids. The field of neuropathic pain research and treatment is in the early stages of development, with many unmet goals. In coming years, several advances are expected in the basic and clinical sciences of neuropathic pain, which will provide new and improved therapies for patients who continue to experience this disabling condition. Table 1 highlights the clinical and pathophysiologic features of common neuropathic pain syndromes that are caused by nerve injury or dysfunction. Knowledge of the cellular and molecular mechanisms of neuropathic pain has advanced with the development of various experimental models of nerve injury. 50 Both peripheral and central mechanisms ( Fig.  2) have been proposed as being relevant to the pathogenesis of neuropathic pain.
Pathophysiology and molecular mechanisms of neuropathic pain

51
Peripheral mechanisms
Regeneration after nerve injury results in the formation of neuromas 52, 53 and sprouting of new nerve projections among uninjured neighbouring neurons. 54 Collateral sprouting then leads to altered sensory properties that may be realized as expanded receptive fields. Uncontrolled neuronal firing after experimental nerve injury is largely attributed to increased expression of sodium channels. This mechanism is supported by several lines of evidence, including blockade of neuropathic pain with sodium-channel-blocking local anesthetics. 55 Demyelination of diseased nerves may be another cause of increased neuronal excitability.
56
In addition to sodium channels, expression of voltagegated calcium channels is also increased following nerve injury. 57 Calcium entry through voltage-gated calcium channels is necessary for the release of substance P 58 as well as glutamate from injured peripheral nerves. Within the dorsal root ganglion, increased expression of the α-2-delta subunit of voltage-gated calcium channels correlates with onset and duration of allodynia. 59 Clinical support of the role of this protein in neuropathic pain arises from the analgesic efficacy of α-2-delta voltage-gated calcium-channel antagonists, gabapentin and pregabalin.
60,61
Central mechanisms
Sustained painful stimuli result in spinal sensitization, 62 which is defined as heightened sensitivity of spinal neurons, reduced activation thresholds and enhanced responsiveness to synaptic inputs (i.e., more likely to transmit pain to the brain). 63 This can manifest in expansion of the affected area, increased response to painful inputs and transmission of pain following nonpainful stimuli. 64 Central sensitization is largely mediated by the N-methyl-Daspartate (NMDA) receptor. Although experimental NMDAreceptor blockade clearly suppresses central sensitization, 65 analgesic efficacy of NMDA antagonists has been disappointing, likely because of the narrow therapeutic window of available agents.
61
Activation of descending pathways (the periaqueductal greyrostral ventromedial medulla) 66 has been shown to reduce pain transmission in animals 67 and humans 68 and is thought to contribute to the analgesic effect of opioids and antidepressants. Paradoxically, this system can also facilitate pain transmission 69 and may contribute to some chronic pain states.
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Sympathetically maintained pain
The importance of the sympathetic nervous system in neuropathic pain has been demonstrated by analgesia following sympathectomy in animals 71 and humans, 72 and by pain exacerbation through activation of the sympathetic nervous system. 73 Sympathetically maintained pain may be explained by sprouting of sympathetic neurons into dorsal root ganglia of injured sensory neurons 74 and postinjury sprouting of sympathetic fibres into the dermis.
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Current management Nonpharmacologic
Although many patients with neuropathic pain pursue complementary and alternative treatments, rigorous evidence supporting efficacy of nondrug therapy is limited. Some reports suggest benefits of conservative interventions such as exercise, 76 transcutaneous electrical nerve stimulation, 77 percutaneous electrical nerve stimulation, 78 graded motor imagery 79 and cognitive behavioural therapy or supportive psychotherapy.
80
Pharmacologic
One approach to estimate treatment efficacy using randomized controlled trial (RCT) data is based on the numberneeded-to-treat (NNT) to obtain at least 50% pain relief in one patient. The NNT concept is hampered by methodologic variability across different RCTs, the short-term nature of most RCTs and the lack of consideration for other important outcomes (e.g., disability, quality of life). Also, most RCTs have involved patients with diabetic peripheral neuropathy and postherpetic neuralgia, and the results do not necessarily apply to all neuropathic pain conditions. 
Antidepressants
Tricyclic antidepressants have repeatedly been shown to reduce neuropathic pain. 81 Analgesic actions may be attributable to noradrenaline and serotonin reuptake blockade (presumably enhancing descending inhibition), NMDA-receptor antagonism and sodium-channel blockade. 82 The NNT is about 3 both for balanced noradrenaline and serotonin reuptake inhibitors (e.g., amitriptyline) and predominantly noradrenaline reuptake inhibitors (e.g., nortriptyline).
61
Selective serotonin reuptake inhibitors (NNT = 6.7)
83 and mixed serotonin-noradrenaline reuptake inhibitors (venlafaxine and duloxetine, 84 NNT = 4.1-5.5) 61 do not appear to be as effective as tricyclic antidepressants.
Anticonvulsants
Based on methodologically flawed trials, carbamazepine and phenytoin have NNTs of 2.1-2.3 for diabetic peripheral neuropathy. 61 Both have significant adverse effects, making them generally poor candidates for first-line therapy. Carbamazepine, however, is still considered first-line therapy for trigeminal neuralgia, a unique neuropathic pain condition (NNT = 1.7). 61 Oxcarbazepine, a newer anticonvulsant structurally related to carbamazepine, may also be useful; however, only one RCT (in diabetic peripheral neuropathy) has been published. 85 Gabapentin, an α-2-delta subunit voltage-gated calciumchannel antagonist, 86 has repeatedly demonstrated analgesic Pregabalin is a gabapentin analogue with a similar mechanism, higher calcium-channel affinity and better bioavailability. 60, 87 Pregabalin was superior to placebo in several RCTs in diabetic peripheral neuropathy and postherpetic neuralgia (NNT = 4.2).
61
RCTs of other anticonvulsants, including valproate, lamotrigine and topiramate, have had equivocal results. 61 
Opioid analgesics
The role of opioid analgesics in neuropathic pain has been controversial. However, a recent meta-analysis provides convincing evidence of benefit.
88 Although 14 short-term RCTs (< 24 hours) showed contradictory results, 8 intermediateterm RCTs (≤ 8 weeks) demonstrated important efficacy. These RCTs demonstrated, on average, a 20%-30% pain reduction. For morphine and oxycodone, the NNT ranged from 2.5 to 2.6.
61 However, beneficial effects on mood, quality of life and disability are not consistent. 89, 90 There were no reports of addiction or abuse in these RCTs, although the risk is likely to be low given the common exclusion criterion of substance abuse history. 88 Currently, there is a dearth of evidence supporting the long-term efficacy of opioids in controlling neuropathic pain. However, the results of a recent retrospective review involving more than 100 patients (most of whom had neuropathic pain) who had received chronic opioid therapy for 1 year or more suggest that many patients may continue to enjoy persistent pain relief with opioids.
91
Tramadol is a weak opioid and a mixed serotoninnoradrenaline reuptake inhibitor. 92 Three RCTs of tramadol for neuropathic pain have yielded an overall NNT of 3.9.
61
Methadone is a synthetic opioid potentially useful for controlling neuropathic pain because of its NMDA-antagonist properties. 93 However, its long half-life (24-36 hours) necessitates extremely careful dose titration. 94 Two small RCTs of methadone demonstrated benefit in managing neuropathic pain, 95, 96 and open-label experience suggests promise in a wide variety of neuropathic pain conditions. 97 
NMDA antagonists
Because of the critical role of NMDA activity in central sensitization, 98 NMDA antagonists hold promise in the management of neuropathic pain. Unfortunately, available agents have limited efficacy and produce intolerable side effects. Ketamine, an intravenous anesthetic with NMDA-antagonist activity, has been found to be effective in small RCTs; however, Hyperglycemia, hyperlipidemia, hypoinsulinemia, growth factor deficiency oxidative stress and autoimmunity progressive demyelination and axonal loss sensory loss, paresthesia, dysesthesias, pain and allodynia [38] [39] [40] Lumbosacral radiculopathy (herniated intervertebral disc)
Lancinating pain radiating into the anterior thigh (L2/3) or lower leg (L4-S1) with motor weakness or sensory loss Complex regional pain syndrome • Type 1 (previously "reflex sympathetic dystrophy" -no definable nerve lesion) • Type 2 (previously "causalgia" -nerve injury)
Regional (e.g., limb) pain together with edema, cutaneous blood flow and sweating abnormalities 46 • "Coupling" of sympathetic neurons with injured sensory neurons at peripheral neuroma sites or dorsal root ganglion sites of injured afferent nerves development of noradrenergic sensitivity following nerve injury • Pain, allodynia, hyperalgesia, edema, cutaneous blood flow and sweating abnormalities 47 Postsurgical neuropathic pain (surgical procedure)
Peri-incisional sensory loss, pain and allodynia for more than 3 months after surgery; phantom pain following amputation or mastectomy
• Phantom pain in 30%-81% of amputations 48 • Thoracotomy pain in 11%-57% 48 • Postherniorrhaphy in 37% or less 48 • Postmastectomy pain in 66%-83% 48 • Poststernotomy in 54% or less 49 psychomimetic side effects are dose limiting. 99 Dextromethorphan, a common cough suppressant and NMDA antagonist, has produced uncertain results in controlling neuropathic pain, showing modest benefit in diabetic peripheral neuropathy, but not in postherpetic neuralgia.
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Topical agents
Locally acting analgesics are attractive because they may cause minimal systemic side effects. The lidocaine patch 5% has been shown to relieve localized pain in postherpetic neuralgia with no increase in side effects (NNT = 4.4).
61 Although the lidocaine patch 5% is not available in Canada, pharmacists can make up the gel or cream at a concentration of 5%-10%. 101 Capsaicin, an ingredient of hot peppers, has shown mixed results in RCTs, 61 and some patients with postherpetic neuralgia have reported pain exacerbation. One RCT evaluating topical doxepin, capsaicin and their combination demonstrated significant analgesia with all 3 of these interventions.
102
Miscellaneous drugs
Mexiletine, an oral antiarrhythmic agent and sodium-channel blocker, was superior to placebo in only 2 of 7 RCTs. 61 Clonidine, an α-2-agonist sympathetic blocker, was shown to be effective in a subset of patients with diabetic peripheral neuropathy. 103 Cannabinoids have been found to play a role in ex- Neuropathic pain arises following nerve injury or dysfunction. A: After nerve damage, transcription and axonal trafficking of sodium channels to the site of injury is increased, with concomitant attenuation of potassium channels. The altered expression of ion channels results in neurons becoming hyperexcitable and generating ectopic activity, which is thought to lead to the genesis of spontaneous and paroxysmal pain. B: At the cell body of primary afferent neurons within the dorsal root ganglia (DRG), sympathetic neuronal sprouting occurs and may account for sympathetically maintained pain. C: Peripheral nerve injury causes a multitude of changes in gene transcription and activation of various kinases and proteins, including enhanced N-methyl-D-aspartate (NMDA) receptor activity. However, nerve injury also elicits hypertrophy and activation of glial cells, including microglia within the grey matter of the spinal cord. Microglia express P2X4 purinergic receptors, allowing them to be activated by adenosine triphosphate (ATP). Following activation, microglia release various pronociceptive cytokines, such as interleukin-1 (IL-1), tumour necrosis factor alpha (TNF-α) and neurotrophins, including brain-derived neurotrophic factor, which in turn exacerbates nociceptive transmission and contributes to the sensitization and maintenance of neuropathic pain. Note: Aβ = A beta neuron, Aδ = A delta neuron, C = C nociceptor, 5HT = serotonin, KCC2 = chloride transporter, NA = noradrenaline, Na v = sodium channel, NO = nitric oxide, K v = potassium channel, PGs = prostaglandins, PKs = protein kinases, P2X4 = purinergic receptor.
perimental pain modulation, 105 and there is growing evidence of their efficacy in managing neuropathic pain. The cannabinoid dronabinol provided modest analgesic benefit in an RCT of central pain in multiple sclerosis. 106 An oromucosal spray containing a mixture of tetrahydrocannabinol and cannabidiol provided modest benefit in another RCT of central pain in multiple sclerosis 107 and in an RCT of neuropathic pain following brachial plexus avulsion.
108
Comparative trials
Given the limitations of comparing treatments across trials using NNTs, several investigators have compared treatments within single trials. For example, 3 comparative RCTs suggest that analgesia with desipramine 109, 110 or nortriptyline 111 is comparable to that of amitriptyline but with fewer side effects. Other studies suggest that opioids may be more efficacious than tricyclic antidepressants 112 or gabapentin 16 and that gabapentin is comparable to amitriptyline 113 and venlafaxine analgesia is comparable to that of imipramine.
114 These are, however, early impressions from small RCTs. Larger RCTs that incorporate head-to-head comparisons are needed.
Combination pharmacotherapy
Given the limited effectiveness of current treatments, combining different drugs may result in improved results at lower doses and with fewer side effects. Many patients with neuropathic pain currently receive drug combinations, 115 albeit in the absence of supportive evidence. In a recent RCT, analgesia with a morphine-gabapentin combination was superior to treatment with either drug alone. 16 In a study involving 11 patients who did not respond to gabapentin, a gabapentinvenlafaxine combination was superior to gabapentin alone.
116
In another RCT, the addition of the neuroleptic fluphenazine to amitriptyline therapy provided no benefit. 117 Future trials are needed to evaluate optimal drug combinations and dose ratios as well as safety, compliance and cost-effectiveness.
118
Trigeminal neuralgia and other paroxysmal pain
Trigeminal neuralgia and glossopharyngeal neuralgia (idiopathic or related to multiple sclerosis) are unique conditions. They are characterized by orofacial, paroxysmal, shock-like pains triggered by light, localized, tactile stimulation with minimal constant pain between paroxysms. These syndromes are also distinguished by their high responsiveness to carbamazepine. 119 Baclofen is a muscle relaxant shown to be useful in trigeminal neuralgia in the setting of resistance to carbamazepine. 104 High success rates have also been reported following invasive treatments such as microvascular decompression, trigeminal ganglion balloon compression and stereotactic (gamma knife) radiosurgery.
120
Interventional pain management
Although rigorous supportive evidence is limited, more invasive treatments may be considered for patients with intractable neuropathic pain. 121, 122 Procedures include epidural or perineural injections of local anesthetics or corticosteroids, implantation of epidural and intrathecal drug delivery systems, neural ablative procedures (e.g., Gasserion ganglion glycerol injection or gamma knife surgery) and insertion of spinal cord stimulators, just to name a few. Consideration of highly invasive procedures such as insertion of intrathecal infusion pumps or spinal cord stimulators is generally reserved for patients with no surgically treatable pathology who have failed more conservative treatments and undergone psychological evaluation. 123 Although this level of caution may also be applied to nerve block procedures, some conditions could warrant nerve blocks earlier in the clinical course. For example, sympathetic nerve blocks in early complex regional pain syndrome may be a crucial adjunct for the facilitation of physiotherapy and rehabilitation.
124
Approach to neuropathic pain management in primary care
No single drug works for all neuropathic pain states, and given the diversity of pain mechanisms, patient responses and diseases, treatment must be individualized. Other than analgesia, factors to consider when individualizing therapy include tolerability, other benefits (e.g., improved sleep, mood and quality of life), low likelihood of serious adverse events and cost-effectiveness to the patient and the health care system. 61 The evidence-based approach presented here may require revision as newer treatments and clinical evidence become available.
Pain management requires ongoing evaluation, patient education and reassurance. Diagnostic evaluation of treatable underlying conditions (e.g., spinal cord compression, herniated disc, neoplasm) should continue concurrently with pain management. Patients require education regarding the natural history of their condition and realistic treatment expectations (e.g., current treatments are not curative and analgesia is rarely complete). Even a 30% pain reduction is clinically important to patients. 125 Pain severity, patient complexity (e.g., coexisting depression or substance abuse), failure of attempted treatments and availability of health care resources should be considered when planning referrals to pain clinics and related specialists. Patient compliance and adequacy of analgesic drug titrations (e.g., dose and duration of treatment) should be continually evaluated and documented.
Neuropathic pain is best managed with a multidisciplinary approach. Nevertheless, several different treatments can be initiated in the primary care setting (Fig. 3) . Treatments with the lowest risk of adverse effects should be tried first. Evidence supporting conservative nonpharmacologic treatments (e.g., physiotherapy, exercise, transcutaneous electrical nerve stimulation) is limited; however, given their presumed safety, nonpharmacologic treatments should be considered whenever appropriate. 61 Simple analgesics (e.g., acetaminophen, NSAIDs) are usually ineffective in pure neuropathic pain but may help with a coexisting nociceptive condition (e.g., sciatica with musculoskeletal low-back pain). Early referrals to a pain clinic for nerve blocks may be warranted in some cases to facilitate physiotherapy and pain rehabilitation.
Topical treatment with lidocaine, indicated for postherpetic neuralgia and focal neuropathy, could be tried first if it is available at a cost reasonable to the patient. For other neuropathic pain diagnoses or lidocaine treatment failures, we recommend initiating oral monotherapy with gabapentin or pregabalin, a tricyclic antidepressant, or a mixed serotonin-noradrenaline reuptake inhibitor. Of these treatments, gabapentin or pregabalin appear to be the best tolerated, with very few drug interactions. Tricyclic antidepressants appear to be more efficacious and much less expensive but have a higher likelihood of adverse effects and are relatively contraindicated for use in patients with serious cardiovascular disease (a screening electrocardiogram is recommended before prescribing tricyclic antidepressants), postural hypotension, urinary retention and angle-closure glaucoma. Among available tricyclic antidepressants, nortriptyline and desipramine are more highly recommended because of fewer side effects. Newer mixed serotonin-noradrenaline reuptake inhibitors (e.g., venlafaxine, duloxetine) may not be as efficacious as tricyclic antidepressants but appear to be better tolerated.
Little is known about whether the response to one drug predicts the response to another. However, if the first oral medication tried is ineffective or not tolerated, one might switch to alternate monotherapy. In the event that all of the first-line oral monotherapies tried are ineffective or poorly tolerated, we would then recommend initiating monotherapy with tramadol or an opioid analgesic. Long-term prescribing of opioid analgesics requires special prescribing and regulatory considerations. [126] [127] [128] [129] In Canada, where tramadol is available only as a fixed-dose combination with acetaminophen, the upper dose limit of tramadol will be dic- Consider nonpharmacologic treatments (e.g., physiotherapy, psychological interventions) and, in some cases, early referral for nerve blocks to facilitate rehabilitation (e.g., complex regional pain syndrome) Fig. 3 : Algorithm for the management of neuropathic pain in primary care. Note: CYP450 = cytochrome P450 enzyme, MAOI = monoamine oxidase inhibitor, SNRI = mixed serotonin-noradrenaline reuptake inhibitor, FDA = Food and Drug Administration, CBC = complete blood count, SSRI = selective serotonin reuptake inhibitor. *This is a nonexhaustive list that includes medications recommended in Fig. 3 .
tated by the risk of acetaminophen-related hepatotoxicity (i.e., < 4000 mg acetaminophen). Although supportive evidence is limited, polypharmacy may be helpful. Therefore, in the event of a partial response to any single drug, one could add an alternate drug. If none of the above tried treatments is effective or tolerated, referral to a pain clinic is warranted for consideration of thirdline drugs, interventional treatments and pain rehabilitation programs. Table 2 provides basic information on drugs recommended in Fig. 3 . Given the potential for drug interactions, 130 a thorough review of the patient's current medications is warranted before prescribing any drugs for neuropathic pain. Given the potential for overdose toxicity with opioids and tricyclic antidepressants, suicide risk should be evaluated before prescribing. Some patients need reassurance that analgesia with antidepressants and anticonvulsants does not necessarily imply a diagnosis of depression or epilepsy. Because the central nervous system is depressed by most tricyclic antidepressants, anticonvulsants and opioids, gradual drug dose titration over weeks, toward a maximal tolerated dose, allows for accommodation to adverse effects while reaching an effective dose. Because of this need for gradual dose titration, the physician and patient need to recognize that onset of pain relief will be gradual. If possible, nursing resources should be devoted to weekly patient contact to guide dose titration. Since tricyclic antidepressants are rapidly metabolized in some patients, plasma tricyclic antidepressant levels should be measured if no analgesic or adverse effects are observed at maximal doses so as to safely guide further dose increases. 131 In elderly people, drug treatment should be started at the lowest possible dose and be increased very slowly (i.e., longer titration period) to minimize the risk of falling and related trauma.
Prescribing considerations
Conclusion
Neuropathic pain is a devastating chronic condition that generally can be diagnosed by history and findings on physical examination. For some neuropathic pain syndromes, available treatments are tolerable and afford meaningful relief to a considerable proportion of patients. Nevertheless, many patients report intractable and severe pain, and better treatment strategies are desperately needed. 132 The field of neuropathic pain research and treatment is in the early stages of development, with many goals yet to be achieved. In particular, future laboratory, clinical and epidemiologic 3, 9 research into pathogenesis, 64,136 treatment 2,18,118,137,138 and prevention [133] [134] [135] of neuropathic pain is expected as well as improved dissemination of new information to health professionals and the public. Over the years to come, many upcoming advances are expected in the basic and clinical science of neuropathic pain as well as in the implementation of improved therapies for patients who continue to experience these devastating conditions.
